Zhiqin Deng

Zhiqin Deng

Auto-generated profile, based on publicly available information

Zhiqin Deng

Department of Chemistry, City University of Hong Kong, Hong Kong SAR, P. R. China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ZDZhiqin Deng
Zhiqin Deng
NWNa Wang
Na Wang
YLYingying Liu
Yingying Liu
ZXZoufeng Xu
Zoufeng Xu
ZWZhigang Wang
Zhigang Wang
Guangyu ZhuGuangyu Zhu
Guangyu Zhu

22 June 2023 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
ZDZhiqin Deng
Zhiqin Deng
HLHuangcan Li
Huangcan Li
SCShu Chen
Shu Chen
NWNa Wang
Na Wang
GLGongyuan Liu
Gongyuan Liu
Guangyu ZhuGuangyu Zhu
Guangyu Zhu

1 December 2019 in Chem
Verified
Journal Article
Closed access
ZWZhigang Wang
Zhigang Wang
NWNa Wang
Na Wang
SCShun-Cheung Cheng
Shun-Cheung Cheng
KXKai Xu
Kai Xu
ZDZhiqin Deng
Zhiqin Deng
GZGuangyu Zhu
Guangyu Zhu

7 January 2019 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
ZWZhigang Wang
Zhigang Wang
ZDZhiqin Deng
Zhiqin Deng
Guangyu ZhuGuangyu Zhu
Guangyu Zhu
Cisplatin plays a pivotal role in the treatment of various malignant tumors, but its therapeutic effects are hampered by drug resistance. Pt(IV) prodrugs represent a promising class of “non-conventional” platinum-based anticancer agents to circumvent drug resistance, which can be easily functionalized with other bioactive ligands. One strategy is to build “dual-action” and “multi-action” Pt(IV) prodrugs that not only damage DNA but also perturb other pathways related to cisplatin resistance to achieve combinatorial therapeutic effects. Another way to overcome the shortcomings of cisplatin is to deliver Pt(IV) prodrugs via nanocarriers. Most studies in this area have focused on designing prodrugs based on the mechanism of cisplatin resistance within isolated cancer cells. Recent findings, however, reveal that the tumor microenvironment also plays important roles in the development of cisplatin resistance. This perspective focuses on various types of novel cisplatin-based Pt(IV) complexes, including Pt-loaded nanostructures, to overcome cisplatin resistance. Special attention will be devoted to complexes that target the tumor microenvironment, which is a new area for the development of effective Pt(IV) prodrugs. Our summary and outlook may have a hope to help researchers in the field generate new ideas and strategies to develop more potent Pt(IV) prodrugs to combat cisplatin resistance.

23 June 2023 in Science Advances
Verified
Journal Article
Open access
GLGongyuan Liu
Gongyuan Liu
YZYachao Zhang
Yachao Zhang
HYHouzong Yao
Houzong Yao
ZDZhiqin Deng
Zhiqin Deng
SCShu Chen
Shu Chen
Guangyu ZhuGuangyu Zhu
Guangyu Zhu
Despite the great success achieved by photoactivated chemotherapy, eradicating deep tumors using external sources with high tissue penetration depth remains a challenge. Here, we present cyaninplatin, a paradigm of Pt(IV) anticancer prodrug that can be activated by ultrasound in a precise and spatiotemporally controllable manner. Upon sono-activation, mitochondria-accumulated cyaninplatin exhibits strengthened mitochondrial DNA damage and cell killing efficiency, and the prodrug overcomes drug resistance as a consequence of combined effects from released Pt(II) chemotherapeutics, the depletion of intracellular reductants, and the burst of reactive oxygen species, which gives rise to a therapeutic approach, namely sono-sensitized chemotherapy (SSCT). Guided by high-resolution ultrasound, optical, and photoacoustic imaging modalities, cyaninplatin realizes the overall theranostics of tumors in vivo with superior efficacy and biosafety. This work highlights the practical utility of ultrasound to precisely activate Pt(IV) anticancer prodrugs for the eradication of deep tumor lesions and broadens the biomedical uses of Pt coordination complexes.

14 December 2020 in Nature Catalysis
Verified
Journal Article
Closed access
PDF file
XLXingguang Li
Xingguang Li
MDMeng Duan
Meng Duan
ZDZhiqin Deng
Zhiqin Deng
QSQianzhen Shao
Qianzhen Shao
MCMin Chen
Min Chen
JSJianwei Sun
Jianwei Sun